为了探讨血清LDH-3同功酶作为慢性粒细胞白血病肿瘤标志物的临床价值、评价一种判定LDH-3异常的更全面的诊断标准,作者选择58例慢粒白血病住院患者,按照Kantarjian 等人提出的方法将他们分为六个临床期:(1)28例为慢性期;(2)6例为强化治疗前的急速进展期;(3)4例为强化治疗前幼细胞危象期;(4)2例为治疗后幼细胞危象期;(5)10例为部分缓解期;(6)8例为完全缓解期。前三组被认为 To investigate the clinical value of serum LDH-3 isozyme as a tumor marker of chronic myelogenous leukemia and to evaluate a more comprehensive diagnostic criteria for determining LDH-3 abnormalities, the authors selected 58 hospitalized patients with chronic myeloid leukemia, according to Kantarjian et al. The proposed method divides them into six clinical phases: (1) 28 patients are in the chronic phase; (2) 6 patients are in rapid progression before intensive treatment; (3) 4 patients are in intensive treatment of premature crises; (4) 2 cases of post-treatment juvenile cell crisis; (5) 10 cases of partial remission; (6) 8 cases of complete remission. The first three groups are considered